Bonesupport Holding AB (publ) (BONEX.ST)
SEK 382.8
(2.03%)
SEK 382.8
(2.03%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 13.93 Million SEK | 132.83% |
| 2022 | -67.6 Million SEK | 20.06% |
| 2021 | -84.57 Million SEK | 12.08% |
| 2020 | -96.19 Million SEK | 39.01% |
| 2019 | -157.71 Million SEK | 9.57% |
| 2018 | -174.4 Million SEK | -75.66% |
| 2017 | -99.28 Million SEK | -11.88% |
| 2016 | -88.74 Million SEK | -64.63% |
| 2015 | -53.9 Million SEK | -37.15% |
| 2014 | -39.3 Million SEK | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q3 | 40.96 Million SEK | 37.85% |
| 2024 Q1 | 32.29 Million SEK | 768.95% |
| 2024 Q2 | 29.71 Million SEK | -7.97% |
| 2023 Q2 | 5.95 Million SEK | 675.0% |
| 2023 Q4 | 3.71 Million SEK | -75.01% |
| 2023 FY | 22.19 Million SEK | 132.83% |
| 2023 Q1 | 768 Thousand SEK | 103.44% |
| 2023 Q3 | 14.86 Million SEK | 149.8% |
| 2022 Q3 | -13.94 Million SEK | 6.15% |
| 2022 Q4 | -22.35 Million SEK | -60.35% |
| 2022 FY | -67.6 Million SEK | 20.06% |
| 2022 Q2 | -14.85 Million SEK | 9.73% |
| 2022 Q1 | -16.45 Million SEK | 24.42% |
| 2021 Q2 | -25.94 Million SEK | -31.84% |
| 2021 Q4 | -21.77 Million SEK | -63.95% |
| 2021 Q1 | -19.67 Million SEK | 26.19% |
| 2021 FY | -84.57 Million SEK | 12.08% |
| 2021 Q3 | -13.28 Million SEK | 48.8% |
| 2020 Q1 | -29.2 Million SEK | 24.33% |
| 2020 FY | -96.19 Million SEK | 39.01% |
| 2020 Q4 | -26.65 Million SEK | -38.65% |
| 2020 Q3 | -19.22 Million SEK | 18.09% |
| 2020 Q2 | -23.47 Million SEK | 19.63% |
| 2019 Q1 | -38.99 Million SEK | 15.84% |
| 2019 FY | -157.71 Million SEK | 9.57% |
| 2019 Q4 | -38.59 Million SEK | -18.08% |
| 2019 Q3 | -32.68 Million SEK | 31.64% |
| 2019 Q2 | -47.82 Million SEK | -22.63% |
| 2018 Q4 | -46.33 Million SEK | 18.87% |
| 2018 FY | -174.4 Million SEK | -75.66% |
| 2018 Q1 | -33.13 Million SEK | 0.75% |
| 2018 Q2 | -37.82 Million SEK | -14.16% |
| 2018 Q3 | -57.11 Million SEK | -51.02% |
| 2017 Q3 | -20.11 Million SEK | -9.55% |
| 2017 Q1 | -27.43 Million SEK | 3.4% |
| 2017 Q2 | -18.36 Million SEK | 33.07% |
| 2017 Q4 | -33.38 Million SEK | -65.96% |
| 2017 FY | -99.28 Million SEK | -11.88% |
| 2016 Q2 | -20.82 Million SEK | -52.46% |
| 2016 FY | -88.74 Million SEK | -64.63% |
| 2016 Q4 | -28.39 Million SEK | -9.81% |
| 2016 Q3 | -25.86 Million SEK | -24.18% |
| 2016 Q1 | -13.66 Million SEK | 0.0% |
| 2015 FY | -53.9 Million SEK | -37.15% |
| 2014 FY | -39.3 Million SEK | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| AddLife AB (publ) | 585 Million SEK | 97.619% |
| Biotage AB (publ) | 376 Million SEK | 96.295% |
| Doxa AB (publ) | 269.4 Million SEK | 94.829% |
| Elekta AB (publ) | 2.03 Billion SEK | 99.317% |
| iZafe Group AB (publ) | -35.63 Million SEK | 139.091% |
| Ortivus AB (publ) | -17.61 Million SEK | 179.094% |
| Ortivus AB (publ) | -17.61 Million SEK | 179.094% |
| Q-linea AB (publ) | -230.58 Million SEK | 106.041% |
| S2Medical AB (publ) | -15.26 Million SEK | 191.261% |
| Synsam AB (publ) | 696 Million SEK | 97.999% |